192 filings
6-K
OKYO
OKYO Pharma Limited
12 Feb 25
Current report (foreign)
7:00am
6-K
OKYO
OKYO Pharma Limited
31 Jan 25
OKYO Pharma Announces Chairman and CEO Acquire Shares
7:00am
6-K
OKYO
OKYO Pharma Limited
29 Jan 25
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
4:30pm
6-K
OKYO
OKYO Pharma Limited
22 Jan 25
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
7:00am
6-K
OKYO
OKYO Pharma Limited
26 Nov 24
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
7:00am
6-K
aeqy7 7aj
30 Oct 24
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
7:00am
6-K
91knm m9quqdnl4zct
23 Oct 24
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
7:00am
6-K
p6c xmomce71
16 Oct 24
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
7:00am
6-K
wzv7jdi3
10 Sep 24
OKYO Pharma Announces Chairman Acquires Shares
7:00am
6-K
ia1 blln1g6
5 Sep 24
OKYO Pharma Announces Chairman Acquires Shares
7:00am
6-K
carfc42smd35559 sf
27 Aug 24
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
7:00am
6-K
wzzwoevo zd2
23 Aug 24
Current report (foreign)
9:00am
6-K
bsq7d5cge
23 Aug 24
OKYO Pharma Announces Chairman Acquires Shares
7:00am
6-K
1offu fjsbv633icg
21 Aug 24
OKYO Pharma Announces Chairman Acquires Shares
7:00am
6-K
0n3zy jv9ebm2mm6s50w
15 Aug 24
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
1:21pm
6-K
aa3re1fy
6 Aug 24
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
7:00am
NT 20-F
r6leyse
31 Jul 24
Notice of late annual filing (foreign)
5:00pm
6-K
28o5g apgn
11 Jul 24
Current report (foreign)
7:00am
6-K
ip3 6jyxj7v9nwygmm9
10 Jul 24
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
7:00am